Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NurOwn in ALS
NCT02017912Phase 2Completed
- Sponsor
- BrainStorm Cell Therapeutics Inc.
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MSC-NTF in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by BrainStorm Cell Therapeutics Inc. Primary endpoint: Number of Patients With at Least One Treatment Emergent Adverse Events at 24 weeks. Started May 2014; status: completed.
02
Drugs
MSC-NTF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02017912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017912.